Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CNOT7 | Q9UIV1 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509773 | 0.91 | CYP11B1 (0.46) | CYP11B1CYP11B2IDO1GSK3AGSK3B | |
| SCHEMBL18307216 | 0.84 | CYP11B1 (0.49) | CYP11B1CYP11B2ALDH1A1PKMDAO | |
| SCHEMBL1757759 | 0.83 | CYP11B1 (0.66) | CYP11B1CYP11B2IDO1ALDH1A1PKM | |
| SCHEMBL7694608 | 0.81 | CYP11B1 (0.75) | CYP11B1CYP11B2 | |
| SCHEMBL8135755 | 0.79 | CYP11B1 (0.65) | CYP11B1CYP11B2IDO1ALDH1A1 | |
| SCHEMBL7699859 | 0.76 | CYP11B1 (0.50) | CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL5935193 | 0.75 | CYP11B1 (0.63) | CYP11B1CYP11B2IDO1MGLL | |
| SCHEMBL7260734 | 0.75 | CYP11B1 (0.54) | CYP11B1CYP11B2HTTIDO1ALDH1A1 | |
| SCHEMBL6989844 | 0.75 | TSHR (0.48) | CYP11B1CYP11B2HTTIDO1ALDH1A1 | |
| SCHEMBL2780498 | 0.75 | HTT (0.47) | CYP11B1CYP11B2HTTIDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362237-A | Synthesis method of etomidate | 化学与精细化工广东省实验室 | 2024-01-09 | — | — | CN | claimed |
| CN-117362237-A | Synthesis method of etomidate | 化学与精细化工广东省实验室 | 2024-01-09 | — | — | CN | disclosed |
| CN-117362237-A | Synthesis method of etomidate | 化学与精细化工广东省实验室 | 2024-01-09 | — | — | CN | disclosed |
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | LES LABORATOIRES SERVIER (FR) | 2002-10-24 | — | — | US | disclosed |
| EP-1225170-A2 | Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier S.A. (FR) | 2002-07-24 | — | — | EP | disclosed |
| EP-1054882-A1 | CONDENSED HETEROCYCLIC SYSTEM DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041248-A1 | CONDENSED HETEROCYCLIC SYSTEM DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | COASY, FNTA, FNTB | CYP11B1 147/4885CYP11B2 399/4885HTT 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.